Remove 2025 Remove Leads Remove Pharma
article thumbnail

The 2025 Pharma Toolkit for Virtual Medical Education

Impetus Digital

Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. Transform your approach and lead the curve in training!

Education 111
article thumbnail

Cigna's Express Scripts to cross out AbbVie's Humira from some formularies in 2025, opting to go with biosims instead

Fierce Pharma

Following CVS Caremark's lead, Cigna's pharmacy benefit manager unit will nix Humira from formularies in favor of Humira biosimilars from Boehringer Ingelheim, Teva and Sandoz. When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace.

article thumbnail

Adopting AI for R&D in 2025 – what needs to be addressed?

European Pharmaceutical Review

However, the road to successful implementation is fraught with concerns around data privacy, workflow integration, and acceptance by both patients and physicians, stated Sachin Gharat, Associate Project Manager, Pharma at GlobalData. In 2025, organisations must focus on addressing data integrity challenges. 2024; 177: 108632.

article thumbnail

Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’

pharmaphorum

That spend is due to reach of $3 billion by 2025, according to GlobalData analyst Kitty Whitney, who notes that there has been a steady stream of startups formed in the last three to four years to tap into the emerging AI market. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

Marketing 120
article thumbnail

Connected customer data: a golden opportunity for pharma marketers

pharmaphorum

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.

article thumbnail

Chiesi expands rare disease portfolio with Amryt Pharma acquisition

pharmaphorum

is to acquire the 2015-established Amryt Pharma Plc. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. on 6 th January.

Pharma 78
article thumbnail

5 Proven Social Media Marketing Strategies for Pharma Brands

Pharma Marketing Network

But with strict regulations and evolving consumer expectations, how do pharma brands navigate the digital landscape effectively? Pharma professionals should take the time to research and segment their audience. Engage Responsibly and Transparently Engagement is king, but for pharma brands, it’s a delicate dance.

Media 52